H1N1 Recombinant Proteins 

H1N1 recombinant antigens are engineered proteins derived from the influenza A virus, specifically from the hemagglutinin (HA) or neuraminidase (NA) surface glycoproteins of the H1N1 subtype. These antigens are pivotal for studying the immune response to influenza, developing diagnostic assays, and producing vaccines. They provide a safer, non-infectious alternative to native viral components, with high specificity and purity for research and clinical applications.

Content of H1N1 Recombinant Antigen

H1N1 recombinant antigens are expressed in heterologous systems such as E. coli, yeast, or mammalian cells. They typically include functionally and structurally conserved domains, ensuring their ability to mimic the native viral proteins. Recombinant antigens may be full-length or truncated forms (e.g., the HA1 subunit) and are often purified with affinity tags (e.g., His-tag) for experimental use.

Applications of H1N1 Recombinant Antigen

• Vaccine Development
  • Used to produce subunit vaccines by eliciting an immune response against the HA and NA glycoproteins.
• Serological Assays
  • Essential for developing ELISA and lateral flow assays to detect H1N1-specific antibodies in clinical or epidemiological studies.
• Immunogenicity Studies
  • Investigate the antigenic properties of H1N1 strains and evaluate cross-reactivity with other influenza subtypes.
• Drug Discovery
  • Utilized in screening assays to identify inhibitors targeting viral entry or replication mechanisms, particularly hemagglutinin inhibitors.
• Pathogenesis Research
  • Studied to understand the molecular mechanisms of H1N1 infection and host immune evasion strategies.
• Diagnostic Standards
  • Serve as positive controls or calibration standards in diagnostic platforms for influenza A detection.

H1N1 recombinant antigens are indispensable for influenza research, facilitating advancements in vaccine development, diagnostics, and therapeutic strategies to combat seasonal and pandemic influenza outbreaks.